Post-marketing surveillance study collects real-world safety and efficacy data for Xultophy™ (Insulin Degludec/Liraglutide) in Indian Type 2 Diabetes patients.
Background
Type 2 Diabetes Mellitus (T2DM) is a progressive metabolic disorder requiring sustained glycemic control to prevent complications. While various monotherapies exist, many patients eventually require combination treatments to achieve target HbA1c levels. Insulin Degludec/Liraglutide (IDegLira, marketed as Xultophy™) combines a long-acting basal insulin with a GLP-1 receptor agonist, offering a synergistic approach to improve glycemic control while potentially mitigating weight gain and hypoglycemia risks associated with insulin monotherapy. Real-world data, especially from diverse populations like India, are crucial to understand its long-term performance and safety outside controlled clinical trials.
Study Design
This was a non-interventional, post-marketing surveillance study conducted in India, designed to evaluate the long-term safety and efficacy of Xultophy™ (Insulin Degludec/Liraglutide) in routine clinical practice. As an observational study, it did not dictate treatment protocols but rather collected data on how the combination therapy was used and tolerated by patients with Type 2 Diabetes Mellitus under their physicians' care. The study aimed to assess various parameters related to glycemic control and adverse events over an extended period, reflecting real-world patient management and treatment outcomes in a diverse Asian population.
Results
This non-interventional study aimed to evaluate the long-term safety and efficacy of Xultophy™ (Insulin Degludec/Liraglutide) in a real-world setting. The primary objective was to assess glycemic control, typically measured by HbA1c levels, and the incidence of adverse events, including hypoglycemia, over the study duration. Secondary objectives often include changes in body weight, blood pressure, and patient-reported outcomes, providing a comprehensive view of the drug's impact. The study design focused on collecting data from routine clinical practice, reflecting how the combination therapy is used and tolerated outside of controlled trial environments. This approach provides valuable insights into the drug's performance across diverse patient profiles and healthcare settings, which is crucial for understanding its broader clinical utility and safety profile in a large market like India.
The study's core contribution is the collection of real-world evidence on Xultophy™'s long-term performance, offering insights into its practical effectiveness and safety profile in a routine clinical environment.
Key Findings
- Evaluation of long-term glycemic control (e.g.,
HbA1c) in routine clinical practice. - Assessment of the long-term safety profile, including adverse events and hypoglycemia.
- Collection of real-world efficacy data for Xultophy™ in a diverse patient population.
- Insights into the practical use and tolerability of Insulin Degludec/Liraglutide combination therapy.
Why It Matters
Understanding how Xultophy™ (Insulin Degludec/Liraglutide) performs in routine clinical practice, particularly in a large and diverse population like India, is critical for healthcare providers and patients. This real-world evidence complements controlled trial data, offering insights into long-term safety, efficacy, and tolerability under varied conditions and patient adherence patterns. For clinicians, it helps validate treatment decisions and manage patient expectations regarding glycemic control and potential side effects. For individuals using or considering this combination therapy, such studies provide a more realistic picture of its benefits and risks outside of highly selected trial populations, informing personalized treatment strategies and potentially optimizing dosing or co-interventions based on observed outcomes in similar demographics.
xultophy
insulin-degludec
liraglutide
type-2-diabetes
real-world-evidence
post-marketing-surveillance